Fortunately, Gemigliptin, a novel DPP‐4 inhibitor, could efficiently inhibit LECT2 expressions, improve hepatic steatosis and ameliorate insulin resistance by increasing AMPK phosphorylation and reducing CD209 receptor‐mediated JNK pathway. The gene discussed is MAPK8; the disease is fatty liver disease.